Introduction
As one of the most common types of malignant liver tumors, hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third most prevalent cause of cancer-associated mortality worldwide (1) . Of note, the number of Chinese patients with HCC accounts for >50% of global cases of HCC (2) . Each year, an estimate of 21,000 new diagnoses of HCC are posed and 700,000 HCC-associated mortalities occur (3) . As all neoplastic malignancies, HCC is generated via a complex, multi-step process comprising various genetic and epigenetic aberrations which affect a variety of and distinct etiology-specific pathways (4) . Chronic inflammation, multiple viral infections, obesity, chronic alcohol abuse and diabetes are known to be risk factors for HCC (5, 6) . In most cases, current treatment strategies, including hepatectomy or orthotopic liver transplantation, significantly improve the patient's quality of life. However, the overall prognosis remains poor for the majority of HCC patients (7, 8) . Of note, fatal tumor recurrence or metastasis occur in as many as 50% at two years and 75-100% at five years after surgery (9) . In spite of recent advances in functional genomics, which have enhanced the understanding of hepatocarcinogenesis, the molecular pathogenesis of HCC has largely remained elusive (10, 11) . It is therefore required to clarify the underlying mechanisms of HCC, which may lead to the development of improved prognostic tools, identification of novel therapeutic targets and approaches to suppress cancer recurrence.
MicroRNAs (miRNAs/miRs) are non-coding, endogenous, single-stranded RNA molecules of ~22 nucleotides in length, which regulate human gene expression (12) . At present, it is thought that miRNAs potentially regulate almost one third of all coding genes in the human genome (13) . miRNAs generally bind to the 3'-untranslated region (UTR) of target mRNAs through base pairing (14) . In recent years, accumulating evidence has suggested a functional contribution of specific miRNAs in diverse biological processes (15, 16) , including the de-regulation of miRNAs by acting on their targeted genes during the progression and tumorigenesis of human cancers (17, 18) . In addition, an increasing number of studies have demonstrated the differential expression of miRNAs in various cell types and developmental stages, indicating that miRNAs regulate a variety of biological functions and disease-associated processes, including cell proliferation, differentiation, metabolism, programmed cell death and metastasis (19, 20) . Furthermore, miRNAs have been demonstrated to be frequently located in genomic breakpoint regions in human cancers and to act as either oncogenes or tumor suppressor genes during tumorigenesis and cancer progression (21) . miR-148b has been shown to be significantly reduced in HCC (22) . The present investigated the potential role of miR-148b in HCC cells. Therefore, miR-148b was transfected MicroRNA-148b targets Rho-associated protein kinase 1 to inhibit cell proliferation, migration and invasion in hepatocellular carcinoma into HCC cells and its effect on proliferation, migration and invasion were assessed. Furthermore, the present study aimed to identify direct target genes of miR-148b. The present study showed that miR-148b inhibited cell proliferation, migration and invasion in the HepG2 and SMMC-7721 HCC cell lines, indicating a tumor-suppressive role of miR-148b in HCC. The present study also provided the first evidence that miR-148b directly targets Rho-associated protein kinase 1 (ROCK1) in HCC cells.
Materials and methods
Cell culture and transfection. The HepG2 and SMMC-7721 human HCC cell lines were obtained from the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). Cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) in a humidified atmosphere with 5% CO 2 at 37˚C. The mature miR-148b mimics and negative control miRNA mimics (NC) were designed and synthesized by GenePharma (Shanghai, China). The sequence of the miR-148b mimic was as follows: 5'-UCAGUGCAUCA CAGAACUUUGU-3'. The sequence of NC mimic was 5'-UUCUCCGAACGUGUCACGUTT-3'. Prior to transfection, the cells were seeded in a 6-well plate and cultured in RPMI-1640 medium without antibiotics. For functional analysis, the cells were transfected with the miR-148b or NC mimics using Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol.
Cell viability assay. Cell viability was assessed using a 3-(4, 5-dimethylthiazolyl-2-yl)-2-5 diphenyl tetrazolium bromide (MTT; 5 mg/mL) assay. Cells transfected with miR-148b or NC were seeded onto 96-well plates at a density of 3,000 cells per well in a final volume of 100 µl. Following incubation for 24, 48, 72, 96, 120 or 144 h, 20 µl MTT (Sigma-Aldrich, St. Louis, MO, USA) was added to each well. The plates were incubated for 4 h at 37˚C followed by replacement of the medium with 200 µl dimethyl sulfoxide (Sigma-Aldrich). The absorbance at was measured as the optical density (OD) at 490 nm using an automatic multi-well spectrophotometer (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The growth inhibition rate was calculated using the following formula: Inhibitory rate = (1 -OD miR-148b /OD miR-NC ) x100%. Three independent experiments were performed with three replicates in each.
Cell migration and invasion assay. Cell migration and invasion assays were performed in a 24-well Boyden chamber with an 8-µm pore-size polycarbonate membrane (Corning-Costar, Corning, NY, USA). Cells (1x10 5 /well) transfected with miR-148b or NC in 200 µl serum-free RPMI-1640 were seeded into the upper wells of the Transwell compartments with or without Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) coating for the migration and invasion assays, respectively, while 500 µl medium containing 20% FBS was added to the lower chamber. Incubation was performed for 12 and 24 h for the migration and the invasion assay, respectively. Subsequently, cells on the lower side of the membranes were fixed in 100% methanol (Beyotime Institute of Biotechnology, Haimen, China) for 2 min and cells on the upper side of the membranes were removed using cotton swabs. The migrated or invaded cells were stained with 0.5% crystal violet (Beyotime Institute of Biotechnology) for 2 min and images were captured using a light microscope (Olympus IX53; Olympus, Tokyo, Japan). Values for migration and invasion were obtained by counting five fields per membrane and represented as the average of three independent experiments Each experiment was performed at least three times, with each experimental condition repeated in triplicate.
Luciferase reporter assay. A target search for miR-148b using Targetscan (http://www.targetscan.org/) indicated that the 3'UTR of ROCK1 mRNA contains a potential targeted sequence for miR-148b. To experimentally confirm whether ROCK1 is a direct target of miR-148b, a luciferase reporter assay was performed. HepG2 or SMMC-7721 cells were seeded onto a 12-well plate at ~90% confluence and co-transfected with miR-148b or NC, and a luciferase reporter vector (GenePharma, Shanghai, China) containing the wild-type (WT) or mutant (Mut) 3'-UTR of ROCK1, using Lipofectamine 2000 (Invitrogen). Following 48 h of incubation, the cells were harvested and firefly luciferase activity was measured using the Dual Luciferase Assay system (Promega, Madison, WI, USA) with the results normalized to Renilla luciferase activity. Each assay was performed as three replicates.
Western blot analysis. Cells were harvested in radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology) at 72 h after transfection with miR-148b and NC. Following determination of the protein concentration using a bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology), equal quantities of protein (20 µg) were separated by 10% SDS-PAGE (Beyotime Institute of Biotechnology) and electrotransferred onto polyvinylidene difluoride membranes (Beyotime Institute of Biotechnology). The membranes were blocked with 5% non-fat milk, followed by incubation overnight at 4˚C with the following primary antibodies: Rabbit anti-human monoclonal ROCK1 antibody (cat. no. 4035; 1:1,000 dilution; Cell Signaling Technology, Inc., Danvers, MA, USA) and rabbit anti-human monoclonal β actin antibody (cat. no. 8546; 1:1,000 dilution; Cell Signaling Technology, Inc.). After washing with Tris-buffered saline (TBS) three times, incubation with the corresponding horseradish peroxidase-conjugated secondary antibody was performed for 1 h. Following three washes with TBS, the bound secondary antibody was visualized using enhanced chemiluminescence solution (Pierce, Rockford, IL, USA) and images were captured using the FluorChem imaging system (Alpha Innotech, San Leandro, CA, USA). The protein intensities were quantified using AlphaEase FC software. (version 4.1.0; Alpha Innotech).
Statistical analysis.
Values are expressed as the mean ± standard deviation. Differences between groups were assessed using Student's t-test with Stata 10.0 software (Stata Corp., College Station, Texas, USA). A two-tailed P-value of less than 0.05 was considered to indicate a statistically significant difference between values.
Results

miR-148b reduces the proliferation of HCC cell lines.
To assess the effects of miR-148b on cell proliferation, an MTT assay was used. As expected, upregulation of miR-148b significantly inhibited the proliferation of the HepG2 and SMMC-7721 cell lines ( Fig. 1; P<0.05) . Following 144 h of treatment, the suppression rate of miR-148b reached 29.29±2.8% in HepG2 cells and 41.82±3.5% in SMMC-7721 cells.
miR-148b inhibits the migration and invasion of HCC cell lines.
To study the role of miR-148b in the regulation of invasion and migration of HCC cells, HepG2 or SMMC-7721 cells transfected with miR-148b or NC were cultured in Transwells with or without Matrigel, respectively. As shown in Fig. 2 , transfection with miR-148b mimics significantly suppressed migration and invasion of HepG2 and SMMC-7721 cells (P<0.05). These results indicated that miR-148b suppressed the migration and invasion of HCC cells.
ROCK1 is a direct target gene of miR-148b in HCC.
To identify targets of miR-148b in HCC, a target search using Targetscan was performed. ROCK1 was predicted to be a target of miR-148b, as the 3'UTR of its mRNA contains a region with affinity for miR-148b (Fig. 3A) . To verify whether miR-148b directly targets ROCK1, a luciferase reporter assay was performed. miR-148b was shown to significantly inhibit luciferase activity of a reporter vector containing the WT sequence of the ROCK1 3'UTR targeted by miR-148b, while luciferase activity of the reporter vector containing the Mut sequence was not affected by miR-148b in HepG2 and SMMC-7721 cells (Fig. 3B; P<0.05) . Furthermore, western blot analysis was performed to explore whether ROCK1 was decreased after transfection of HCC cell lines with miR-148b mimics. As shown in Fig. 3C , ROCK1 was significantly downregulated in HepG2 and SMMC-7721 after transfection with miR-148b (P<0.05). All of these results provided in vitro evidence for ROCK1 being a direct target gene of miR-148b in HCC cells.
Discussion
miRNA-encoding genes represent ~1% of the genome of various species and aberrant expression of miRNAs is known to be associated with numerous types of cancer (23) . As miRNA expression can be easily tuned using molecular biology techniques, the upregulation of tumor-suppressive miRNAs and silencing of oncogenic miRNAs represents a promising strategy for cancer therapies (24) . Numerous studies have suggested the use of miRNAs as targets or tools for anti-cancer therapy (25) .
miR-148b is a member of the miR-148/152 family, which comprises miR-148a, miR-148b and miR-152 (26). Being 21-22 nucleotides in length, mature members of the miR-148/152 family have an identical seed sequence of 6-7 nucleotides, which binds to target mRNAs (27) . miR-148b is located on chromosome 12q13 and has been linked with numerous human malignancies; microarray analyses have demonstrated that miR-148b is frequently downregulated in various tumor types, including colorectal (28), gastric (29) , pancreatic (30), colon (31) and oral cancer (32), as well as HCC (22) .
Song et al (29) reported that in gastric cancer, the expression of miR-148b was associated with the tumor size and that ectopic expression of miR-148b inhibited cell proliferation by targeting cholecystokinin B receptor (CCKBR) in vitro and in vivo (29) . The same group also reported that in colorectal cancer, miR-148b affected cell proliferation by regulating the expression of CCKBR, whose function is dependent on gastrin (28) . In breast cancer, miR-148b was also shown to inhibit the invasion, resistance to anoikis, extravasation and lung metastasis formation of breast cancer cells (33) . Furthermore, Wu et al (34) revealed that miR-148b increased the radiosensitivity of non-Hodgkin's lymphoma cells. These studies suggested that miR-148b serves as a potential tumor suppressor. Therefore, transfection with miR-148b mimics or administration of pharmaceutical compounds which cause upregulation of miR-148b expression are expected to be effective therapeutic strategies for cancer.
Previous studies have shown that the expression of miR-148b was decreased in HCC tissues compared with that in normal control specimens; in addition, miR-148b expression was shown to be closely associated with HCC vein invasion and the tumor-nodes-metastasis stage (22) . However, the potential function of miR-148b in HCC had remained elusive. The present study revealed that in HCC, miR-148b may function as a tumor suppressor through repression of ROCK1. Transfection with miR-148b mimics resulted in decreased cell proliferation, migration and invasion in HCC cells. These results suggested that miR-148b may represent a molecular marker and therapeutic tool to inhibit metastasis of HCC.
For the development of metastasis, enhanced motility and invasion of tumor cells are required for them to detach from the primary tumor and enter lymph or blood vessels to (35) . Invasion and metastasis of cancer cells are regulated by various molecular pathways, among which the ROCK signaling pathway has a major role (36) . Overexpression of ROCK, the fundamental downstream effector of the small guanine triphosphatase Rho, enhances the invasion and metastasis of various solid tumor cell types, including hepatocellular (37), breast (38) and colon cancers (39) . Inhibiting ROCK may therefore represent a therapeutic approach for these tumor types.
ROCK has been reported to exist as two isoforms, ROCK1 and ROCK2, which are highly homologous with 65% amino acid sequence homology. Furthermore, sequence analysis revealed a 92% similarity of their kinase domains (40, 41) . Human ROCK1 is encoded by chromosome 18 (18q11.1) (42), has been associated with cancer progression and was shown to be overexpressed in several cancer types (43) . In HCC, upregulated expression of ROCK1 was associated with cytoskeleton remodeling as well as the motility and invasiveness of HCC cells (44) . Several studies revealed that ROCK1 functions as an oncogene and is regulated by a number of miRNAs in human cancers. In gastric cancer, Zheng et al (35) revealed that miR-148a suppressed cell invasion and metastasis by directly targeting ROCK1. In bladder cancer and glioma, miR-124 inhibited cell migration and invasion by downregulating the expression of ROCK1 (45, 46) . ROCK1 was also targeted by miRNAs in other types of human cancer, including miR-584 in renal cell carcinoma (47) , miR-335 in neuroblastoma (48) and miR-146a in prostate cancer (49) . The present study revealed that miR-148b suppressed HCC cell proliferation, migration and invasion by directly targeting ROCK1. miR-148b may therefore be used as a biomarker for early detection of tumor recurrence and as a targeted therapeutic to inhibit the invasiveness and metastasis formation of HCC.
In conclusion, the present study is the first, to the best of our knowledge, to show that miR-148b inhibited the proliferation, migration and invasion of HCC cells through reducing ROCK1 expression. Through the identification of a novel target gene of miR-148b, the present study enhanced the current understanding of carcinogenic mechanisms in HCC. The findings of the present study may lead to the development of novel diagnostic and therapeutic approaches for HCC. Further investigation is required to identify additional target genes of miR-148b, and to assess its suitability for use in the treatment of HCC.
